

Evaluation of Primary Prescription Nonadherence Post-discharge from an Inpatient Psychiatry Unit at a Large Urban Community Hospital – an Observational Study

1 **Meghana Ganjam^{1*}, Ysatis Ruiz², Luis G. Allen³, Rosemary Persaud^{4*}**

2 ¹University of Miami, School of Nursing and Health Studies, Miami, FL, United States.

3 ²Department of Health Sciences and Public Health, University of Florida, Gainesville, FL, United
4 States.

5 ³Medical Director, Advent Health Center for Behavioral Health, Orlando, FL, United States.

6 Assistant Clinical Professor of Psychiatry, Florida State University College of Medicine, Tallahassee,
7 FL, United States.

8 ⁴Clinical Pharmacy Specialist, Orlando Health, 2018-Present; Neuroscience Clinical Pharmacist,
9 Advent Health, 2016-2018, Orlando, FL, United States.

10 *** Correspondence:**

11 Meghana Ganjam
12 mxg1583@miami.edu

13 Rosemary Persaud
14 rosemaryapersaud@gmail.com

15 **Number of words:** 1803

16 **Number of figures and tables:** 6

17 **Keywords:** mental illness₁, prescription nonadherence₂, post-discharge₃, psychiatric unit₄,
18 primary nonadherence₅.

19 **Abstract**

20 **Introduction:** Here, we aimed to evaluate primary prescription nonadherence post-discharge from an
21 acute inpatient psychiatric unit. Prescription nonadherence is a concern across all patient care
22 settings, with primary nonadherence defined as not picking up prescribed medication from the
23 pharmacy or not delivering prescriptions to the pharmacy. Secondary nonadherence, defined as
24 filling a prescription but not taking the medication as prescribed, was not tracked in this study. The
25 incidence of nonadherence can vary widely across settings and has been reported to range from 3–
26 86%. This is a particular concern in patients with a primary psychiatric diagnosis both in an
27 outpatient and inpatient setting.

28 **Design:** The prescription fill rate of eligible patients was tracked on days 7 and 21 post-discharge
29 from acute inpatient psychiatric units of an acute care multispecialty urban community teaching
30 hospital.

31 **Results:** In total, 72 patients aged 18 and above (44%, women) were analyzed. A primary
32 nonadherence incidence of 43% was found, which did not vary significantly across the analyzed
33 variables of age, sex, or primary diagnosis.

34 **Conclusion:** Primary nonadherence is a significant issue in this population. Strategies, such as the
35 implementation of “med-to-bed” programs and use of longer acting injectables when appropriate,

36 would help in increasing adherence. Further research, including the evaluation of other variables that
37 affect nonadherence, is needed to identify and develop steps to overcome the obstacles to adherence.
38

39 **1 Introduction**

40 The treatment of psychiatric health conditions is a global health challenge that contributes to 30% of
41 the nonfatal disease burden (1), and mental health problems, such as depression, represent a growing
42 and increasingly important public health concern. Approximately 20.6% (51.5 million) of adults aged
43 18 and over in the US suffer from mental illness in any given year, and approximately 25.5% (13.1
44 million) of these patients suffer from severe mental illness (2). Neuropsychiatric disorders are a
45 leading cause of disability, accounting for 18.7% of years of life lost to disability and premature
46 mortality (3); further, evidence suggests that disorders, such as posttraumatic stress disorder (PTSD)
47 and depression, increase the incidence of heart disease and dementia among other medical conditions
48 (4, 5, 6). The management of psychiatric conditions as well as of the associated physical maladies is
49 made more difficult by the increased incidence of the nonadherence to medication (7) in individuals
50 with a mental health diagnosis. The World Health Organization (WHO) has defined nonadherence as
51 “a case in which a person’s behavior in taking medication does not correspond with agreed
52 recommendations.” The high-risk group in this category of patients comprises of the subset of those
53 who were sick enough to require inpatient psychiatric hospitalization and were then discharged.
54 There have been few studies that were focused on evaluating primary nonadherence in this patient
55 population. These individuals are particularly vulnerable, and nonadherence leads to poor outcomes,
56 including readmission along with an elevated risk of other comorbid conditions (8, 9). The aim of our
57 study was to gauge the incidence of primary nonadherence by evaluating the failure to fill
58 prescriptions for medication within 21 days of discharge from an inpatient psychiatric unit of a large
59 urban community hospital.
60

61 **2 Materials and Methods**

62 **2.1 Study Design**

63 The study population included 73 inpatients from the Central Florida region who were discharged
64 between January 2017 and May 2017 from a psychiatric unit. The study was determined not to
65 require institutional review board oversight. Eligible patients had an overnight or longer stay at either
66 of the two inpatient psychiatric units at the hospital: a 20-bed capacity unit catering to a more elderly
67 or medically complex population and a 24-bed capacity unit catering to a younger and typically less
68 medically complex population. Patients were transferred between these units based on their medical
69 needs and on hospital staffing and were not tracked separately. Eligible patients were discharged with
70 electronic prescriptions for the required medications, which were sent to a pharmacy of the patient’s
71 choice. Patients who were transferred to another medical unit or who were discharged to a structured
72 living facility, such as an assisted living facility or a skilled nursing facility, were excluded. Patients
73 who did not have a pharmacy of choice and who received handwritten or printed prescriptions instead
74 of electronic prescriptions were also excluded. In total, 73 subjects qualified for inclusion over a
75 period of 120 days. The prescription status of one of the subjects could not be verified, and therefore,
76 this subject was excluded from the study.
77

78 **2.2 Data Collection**

79 Pharmacies where the prescriptions were sent were contacted on days 7 and 21 to confirm if
80 prescriptions were picked up. Based on whether the medications were picked up, the prescriptions
81 were coded using binary points (0, not filled and 1, filled); similarly, the medication pickup status
82 was coded for both days 7 and 21 (0, no and 1, yes).
83 Medications that were prescribed for “as needed” (PRN) use were not considered. Over-the-counter
84 medications (such as folic acid and nicotine replacement products) were not considered. Claims-
85 related data and communication with the pharmacy were used to verify whether a refill was not
86 needed for continuing the prescription (refill too early). The dataset did not contain any insurance
87 information. The primary diagnosis of “acute psychosis” was changed to psychosis. Incidental notes
88 were made regarding several patients who were uninsured or underinsured and who did not use
89 insurance to pay for prescriptions. This was addressed in the study by calling pharmacies to verify
90 pickup or noncompliance without having to rely on insurance claims made for prescriptions.

91 **2.3 Variables**

92 The collected patient information included sex, age, and primary diagnosis. No insurance information
93 was collected. Each variable was tested separately because of the small sample size.
94

95 **2.4 Data Analyses**

96 All tests were two-tailed, and a value of 0.05 was set for statistical significance. All tests were
97 performed using IBM SPSS version 21 software (IBM, Armonk, NY, USA).
98

99 **3 Results**

100 The sex distribution of the study population is presented in **Table 1**. The study population included
101 approximately 44% of women and 56% of men. The diagnosed psychiatric disorders in the study
102 population are listed in **Table 2**.

103 The study population included a large proportion of individuals diagnosed with depression (~60%).
104 The adherence to prescription pickup on days 7 and 21 is presented in **Tables 3A and 3B**.
105 Of the 72 subjects, 35 (49%) picked up their prescriptions by day 7 (95% confidence interval, 37%–
106 60%). By day 21, 41 subjects (57%) were noted to have picked up their prescriptions (95%
107 confidence interval, 45%–68%). There was no statistically significant difference in the rate of pickup
108 between men and women ($p = 0.394$) based on the results of a chi-square test of independence (**Table**
109 **4**). Similarly, age was not associated with the rate of pickup, as there was no statistical difference in
110 the age of patients according to whether they picked up their prescriptions ($p = 0.620$) based on an
111 independent t-test for means (**Table 5**). There was no statistical difference in the rate of pickup by
112 primary diagnosis ($p = 0.235$) based on a chi-square test of independence (**Table 6**).

113 **4 Discussion**

114 Prescription medication nonadherence, a major public health concern that is prevalent across
115 different healthcare settings globally, leads to poor outcomes and increased healthcare costs (10). In a
116 2003 report on medication adherence, the WHO noted that “increasing the effectiveness of adherence
117 interventions may have a far greater impact on the health of the population than any improvement in
118 specific medical treatments” (11). In the current study, the observed incidence of primary
119 nonadherence to prescription medications was 43% based on the behavior of not picking up
120 prescriptions 21 days post-discharge. There is a lack of standardization of the appropriate time period
121 between prescription generation and pickup for the measurement of primary nonadherence (12,13).

122 For the purpose of this study, we chose two timepoints, days 7 and 21. Unfilled prescriptions are
123 returned to stock by day 7 at most pharmacies, and the longest period is usually less than 21 days.
124 The differences in primary nonadherence based on the variables that were assessed (age, sex, or
125 primary diagnosis) were not found to be statistically significant. In some prior studies, it was found
126 that primary nonadherence was higher among patients with severe mental illness, such as
127 schizophrenia (14), but this was not the case in this study population. Multiple factors affect
128 nonadherence, including patient beliefs regarding medication efficacy and side effects, ease of
129 accessing the medication, complexity of the medication regimen, socioeconomic status, insurance
130 status, and marital status among others (15,16). Among patients with chronic illness, it is estimated
131 that nearly 50% do not take medications as prescribed (11). This adversely affects disease outcomes
132 across a wide spectrum of chronic diseases, including chronic obstructive pulmonary disorder,
133 cardiovascular disease, hypertension, and diabetes. Nonadherence becomes particularly important in
134 the subset of patients recently discharged from an acute care setting post-stabilization (17, 9). Within
135 this subset of patients, there are limited data on primary nonadherence post-discharge from acute
136 psychiatric facilities in the US. There are several existing obstacles that hinder the accurate tracking
137 of these prescriptions. Fragmented healthcare systems and payers and the slow adaption to electronic
138 medical records and subsequently to electronic prescription among psychiatric hospitals make
139 prescriptions more difficult to track, as do the larger geographic area that psychiatric hospitals
140 usually serve as compared to acute care multispecialty hospitals. Nonadherence in the subset of
141 patients discharged following hospitalization in a psychiatric unit has been shown to lead to worse
142 outcomes, higher costs, and increased readmissions (7, 9, 18, 19). The goal of this study was to
143 determine the incidence of nonadherence in this specific patient population in order to enable
144 healthcare facilities to develop strategies for improving adherence in this vulnerable patient
145 population. Some of the strategies may include a universal “med-to-bed” (20) program, in which all
146 patients receive a supply of the needed medications along with medication-related education at
147 discharge. Other interventions include communication between the hospital physician and patient’s
148 primary care physician prior to discharge and early post-discharge outpatient follow-up appointments
149 with primary care physicians and psychiatrists (11), which would enable the earlier identification of
150 nonadherence. The use of equivalent long-acting injectable formulations (21), with the initial dose
151 administered prior to discharge, is yet another strategy.

152 In 2020, the US spent more than 225 billion dollars on mental health. There are over 170,000
153 residents occupying inpatient and other 24-h residential treatment beds on any given night, which is
154 an average of over 53.6 patients per a population of 100,000 (22). This number does not include
155 patients incarcerated for mental illness. Along with the decrease in the number of available inpatient
156 psychiatric beds over the past several decades, the average length of stay in patients admitted to
157 inpatient acute psychiatric facilities has also decreased from several weeks to ~10 days with most
158 patients staying for shorter durations (23). Individuals with mental health diagnoses account for a
159 disproportionate sum of the total health expenditure even though only a small proportion of this is
160 spent on mental health (24). The 30-day unplanned readmission rate among patients discharged from
161 inpatient psychiatric hospitals is approximately 20% (25).

162 This study has some limitations. Only patients who chose a predesignated pharmacy and who agreed
163 to have their prescriptions sent electronically were included for the ease of tracking. It is unclear
164 whether the inclusion and tracking of other patients would have altered the results. The primary
165 admitting diagnosis alone was used to stratify the patients, and it is unclear if the addition of
166 secondary diagnoses would have altered the results. Insurance data were not accurately collected and
167 were excluded from the study. This could have provided additional factors related to nonadherence.
168 Improving medication adherence is a key path toward improving healthcare, and promoting primary
169 adherence is the first essential step. This study that has assessed primary nonadherence in this

170 important population subset is of value as our results could aid in gauging the severity of this
171 problem and in formulating strategies for improving the delivery of effective healthcare.
172 Improvements in the care of this population will not only improve mental healthcare but will also
173 decrease the overall healthcare expenditure. The hospital where this study was conducted has since
174 implemented a med-to-bed program in order to more effectively serve this patient population.

175 **5 Conflict of Interest**

176 *The authors declare that the research was conducted in the absence of any commercial or financial*
177 *relationships that could be construed as a potential conflict of interest.*

178 **6 Author Contributions**

179 MG - Review of Data, Research and Analysis, References, Documentation and Write up
180 YR - Formatting and References
181 LGA - Supervising Physician
182 RP - Design and Implementation

183 **7 Funding**

184 None.
185

186 **8 References**

- 187 1. Marquez PV, Saxena S. Making Mental Health a Global Priority. *Cerebrum* (2016) 2016:cer-
188 10-16.
- 189 2. SAMHSA. The National Survey on Drug Use and Health: 2019 (2021).
190 [https://www.samhsa.gov/data/sites/default/files/reports/rpt29392/Assistant-Secretary-](https://www.samhsa.gov/data/sites/default/files/reports/rpt29392/Assistant-Secretary-nsduh2019_presentation/Assistant-Secretary-nsduh2019_presentation.pdf)
191 [nsduh2019_presentation/Assistant-Secretary-nsduh2019_presentation.pdf](https://www.samhsa.gov/data/sites/default/files/reports/rpt29392/Assistant-Secretary-nsduh2019_presentation/Assistant-Secretary-nsduh2019_presentation.pdf) [Accessed July 9,
192 2021].
- 193 3. Murray CJL, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The State of US
194 Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors. *JAMA* (2013) 310:591-
195 608. doi: 10.1001/jama.2013.13805
- 196 4. Byers AL, Yaffe K. Depression and Risk of Developing Dementia. *Nat Rev Neurol* (2011)
197 7:323-31. doi: 10.1038/nrneurol.2011.60
- 198 5. Coughlin SS. Post-Traumatic Stress Disorder and Cardiovascular Disease. *Open Cardiovasc*
199 *Med J* (2011) 5:164-70. doi: 10.2174/1874192401105010164
- 200 6. Stewart JC, Perkins AJ, Callahan CM. Effect of Collaborative Care for Depression on Risk of
201 Cardiovascular Events: Data from the IMPACT Randomized Controlled Trial. *Psychosom*
202 *Med* (2014) 76:29-37. doi: 10.1097/PSY.000000000000022
- 203 7. Chapman SCE, Horne R. Medication Nonadherence and Psychiatry. *Curr Opin Psychiatry*
204 (2013) 26:446-52. doi: 10.1097/YCO.0b013e3283642da4
- 205 8. Colom F, Vieta E. Non-adherence in Psychiatric Disorders: Misbehavior or Clinical Feature?
206 *Acta Psychiatr Scand* (2002) 105:161-3. doi: 10.1034/j.1600-0447.2002.1e003.x
- 207 9. Rosen OZ, Fridman R, Rosen BT, Shane R, Pevnick JM. Medication Adherence as a
208 Predictor of 30-Day Hospital Readmissions. *Patient Prefer Adherence* (2017) 11:801-10. doi:
209 10.2147/PPA.S125672
210

- 211 10. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic
212 Impact of Medication Non-adherence by Disease Groups: a Systematic Review. *BMJ Open*
213 (2018) 8:e016982. doi: 10.1136/bmjopen-2017-016982
- 214 11. Brown MT, Bussell JK. Medication Adherence: WHO Cares? *Mayo Clin Proc* (2011) 86:304-
215 14. doi: 10.4065/mcp.2010.0575
- 216 12. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary Nonadherence to Chronic Disease
217 Medications: a Meta-analysis. *Patient Prefer Adherence* (2018) 12:721-31. doi:
218 10.2147/PPA.S161151
- 219 13. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New Prescription
220 Medication Gaps: a Comprehensive Measure of Adherence to New Prescriptions. *Health Serv*
221 *Res* (2009) 44:1640-61. doi: 10.1111/j.1475-6773.2009.00989.x
- 222 14. Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic
223 Medication Non-adherence and its Associated Factors among Patients with Major Psychiatric
224 Disorders: a Systematic Review and Meta-analysis. *Syst Rev* (2020) 9:17. doi:
225 10.1186/s13643-020-1274-3
- 226 15. Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, Variants, and
227 Causes of Nonadherence with Medication: a Challenge for Tailored Interventions. *Patient*
228 *Prefer Adherence* (2013) 7:675-82. doi: 10.2147/PPA.S29549
- 229 16. Wu J-R, Lennie TA, Chung ML, Frazier SK, Dekker RL, Biddle MJ, et al. Medication
230 Adherence Mediates the Relationship Between Marital Status and Cardiac Event-free
231 Survival in Patients with Heart Failure. *Heart Lung* (2012) 41:107-14. doi:
232 10.1016/j.hrtlng.2011.09.009
- 233 17. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and Risk Factors for
234 Medication Nonadherence in Patients with Schizophrenia: a Comprehensive Review of
235 Recent Literature. *J Clin Psychiatry* (2002) 63:892-909. doi: 10.4088/jcp.v63n1007
- 236 18. Heslin KC, Weiss AJ. Hospital Readmissions Involving Psychiatric Disorders, 2012:
237 Statistical Brief #189. In: *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*
238 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US) (2006).
- 239 19. Yalamova I. Post-discharge Medication Adherence in Schizophrenia. *Arch Psychiatry*
240 *Psychother* (2015) 17:39-47. doi: 10.12740/APP/60513
- 241 20. Lash DB, Mack A, Jolliff J, Plunkett J, Joson JL. Meds-to-Beds: the Impact of a Bedside
242 Medication Delivery Program on 30-Day Readmissions. *J Am Coll Clin Pharm* (2019) 2:674-
243 80. doi: 10.1002/jac5.1108
- 244 21. Titus-Lay EN, Ansara ED, Isaacs AN, Ott CA. Evaluation of Adherence and Persistence with
245 Oral Versus Long-Acting Injectable Antipsychotics in Patients with Early Psychosis. *Ment*
246 *Health Clin* (2018) 8:56-62. doi: 10.9740/mhc.2018.03.056
- 247 22. National Association of State Mental Health Program Directors. Trend in Psychiatric
248 Inpatient Capacity, United States and each state, 1970 to 2014, [Nasmhpd.org](https://www.nasmhpd.org).
249 [https://www.nasmhpd.org/sites/default/files/TACPaper.2.Psychiatric-Inpatient-](https://www.nasmhpd.org/sites/default/files/TACPaper.2.Psychiatric-Inpatient-Capacity_508C.pdf)
250 [Capacity_508C.pdf](https://www.nasmhpd.org/sites/default/files/TACPaper.2.Psychiatric-Inpatient-Capacity_508C.pdf) [Accessed July 9, 2021]
- 251 23. Lee S, Rothbard AB, Noll EL. Length of Inpatient Stay of Persons with Serious Mental
252 Illness: Effects of Hospital and Regional Characteristics. *Psychiatr Serv* (2012) 63:889-95.
253 doi: 10.1176/appi.ps.201100412
- 254 24. How do Individuals with Behavioral Health Conditions Contribute to Physical and Total
255 Healthcare Spending? *Milliman.com*. <https://www.milliman.com/>

256 /media/milliman/pdfs/articles/milliman-high-cost-patient-study-2020.ashx [Accessed July 9,
257 2021].

258 25. Winterstein AG, Bussing R, Goodin A, Xu D, Keenan M, Turner K, et al. Development and
259 Validation of an Administrative Claims-Based Measure for All-Cause 30-Day Risk-
260 Standardized Readmissions after Discharge from Inpatient Psychiatric Facilities. *Med Care*
261 (2020) 58:225-33. doi: 10.1097/MLR.0000000000001275

262
263
264
265
266
267

268 **9 Tables**

269 **Table 1.** Sex distribution of the study population

		Frequency	Percent	Cumulative percent
Valid	Female	32	43.8	43.8
	Male	41	56.2	100.0
	Total	73	100.0	

270
271
272
273

Table 2. Description and frequency of common psychiatric disorders in the study population

	Frequency	Percent	Cumulative percent
Bipolar	12	16.4	16.4
Depression/SI	43	58.9	75.3
Psychosis	7	9.6	86.3
Schizophrenia/Schizoaffective	10	13.7	100.0
Total	73	100.0	

274 Abbreviations: SI, suicidal ideation

275
276 **Table 3A.** Adherence to prescription pickup by day 7

	Frequency	Percent	Valid percent	Cumulative percent
--	-----------	---------	---------------	--------------------

Valid	No	37	50.7	51.4	2774
	Yes	35	47.9	48.6	278
	Total	72	98.6	100.0	279
Missing	System	1	1.4		280
	Total	73	100.0		281
					282
					283
					284
					285

286
287
288
289
290

Table 3B. Adherence to prescription pickup by day 21

		Frequency	Percent	Valid percent	Cumulative percent
Valid	No	31	42.5	43.1	291
	Yes	41	56.2	56.9	292
	Total	72	98.6	100.0	293
Missing	System	1	1.4		294
	Total	73	100.0		295
					296
					297
					298
					299
					300
					301
					302

Table 4.

304 Association between sex and prescription pickup

			Pickup		Total
			No	Yes	
Sex	F	Count	12	20	305
		% within sex	37.5%	62.5%	100.0%
	M	Count	19	21	306
		% within sex	47.5%	52.5%	100.0%
Total		Count	31	41	307
		% within sex	43.1%	56.9%	100.0%

315
316 **Table 5.** Association between age and prescription pickup

	Pickup	N	Mean	Std. deviation	Std. error mean
Age	No	31	50.84	9.832	1.766
	Yes	41	49.41	13.439	2.099

318 Abbreviations: Std., standard

319

320
321
322
323
324
325
326

Table 6. Association between primary diagnosis and prescription pickup

Primary diagnosis			Pickup		Total
			No	Yes	
Bipolar	Count		6	6	12
	% within sex		50.0%	50.0%	100.0%
Depression/SI	Count		14	28	42
	% within sex		33.3%	66.7%	100.0%
Psychosis	Count		5	3	8
	% within sex		62.5%	37.5%	100.0%
Schizophrenia/schizoaffective	Count		6	4	10
	% within sex		60.0%	40.0%	100.0%
Total		Count	31	41	72
		% within sex	43.1%	56.9%	100.0%
Chi-square test	Value	df	Asymp. Sig. (2-sided)		
Pearson chi-square	4.260 ^a	3	.235		
Likelihood ratio	4.272	3	.234		
No. of valid cases	72				

327 Abbreviations: SI, suicidal ideation
328

329 **1 Data Availability Statement**

330 The data that support the findings of this study are available from the corresponding authors (MG and
331 RP) upon reasonable request.
332
333